BIOGEN INC. - COMMON STOCK

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

20 Nov 2024 08:45:06 By NetDania Notify

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

19 Nov 2024 08:45:08 By NetDania Notify

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

19 Nov 2024 00:00:14 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

18 Nov 2024 08:46:07 By NetDania Notify

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

15 Nov 2024 09:03:11 By NetDania Notify

Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease

14 Nov 2024 10:23:15 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

14 Nov 2024 08:45:06 By NetDania Notify

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

13 Nov 2024 08:45:09 By NetDania Notify

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

12 Nov 2024 08:45:39 By NetDania Notify

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

04 Nov 2024 08:46:03 By NetDania Notify

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

01 Nov 2024 08:45:14 By NetDania Notify

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

31 Oct 2024 08:45:50 By NetDania Notify

Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference

30 Oct 2024 18:30:12 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

30 Oct 2024 08:45:21 By NetDania Notify

Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases

29 Oct 2024 17:00:23 By Nasdaq GlobeNewswire

Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer

29 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Michael McDonnell, Executive Vice President and Chief Financial Officer to Retire in February 2025

28 Oct 2024 07:30:00 By Nasdaq GlobeNewswire

Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024

26 Oct 2024 19:15:00 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

25 Oct 2024 15:10:18 By NetDania Notify

Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual Conference

24 Oct 2024 06:30:00 By Nasdaq GlobeNewswire